News - Bristol-Myers Squibb

Filter

Current filters:

Bristol-Myers Squibb

Popular Filters

120 to 144 of 222 results

UK's NICE plans to back NHS use of two breakthrough skin cancer treatments

01-11-2012

The UK's drugs watchdog the National Institute for Health and Clinical Excellence (NICE) this morning…

Bristol-Myers SquibbEuropeOncologyPharmaceuticalPricingRegulationRocheYervoyZelboraf

Bristol-Myers goes into red, on charges and Plavix sales slump

25-10-2012

US drug major Bristol-Myers Squibb (NYSE: BMY) reported financial results for the third quarter of 2012,…

Bristol-Myers SquibbFinancialPharmaceutical

Type 2 diabetes drug sales to almost double to nearly $50 billion in 2021

16-10-2012

The type 2 diabetes drug market will nearly double over the next decade, increasing from $26 billion…

AstraZenecaBristol-Myers SquibbcanagliflozindapagliflozinDiabetesJanuviaJohnson & JohnsonMarkets & MarketingMerck & CoPharmaceutical

Top executive appointments at Boehringer and Bristol-Myers

01-10-2012

German family-owned drug major Boehringer Ingelheim says that Engelbert Tjeenk Willink, a member of the…

Boehringer IngelheimBristol-Myers SquibbManagementPharmaceutical

FDA sets March 2013 PDUFA date for re-submitted Eliquis

28-09-2012

The US Food and Drug Administration has acknowledged receipt of the New Drug Application resubmission…

Bristol-Myers SquibbCardio-vascularEliquisNorth AmericaPfizerPharmaceuticalRegulation

Bristol-Myers links with Vanderbilt for Parkinson's research

23-09-2012

US drug major Bristol-Myers Squibb (NYSE: BMY) has signed up for a collaboration with Vanderbilt University…

Bristol-Myers SquibbNeurologicalPharmaceuticalResearch

Yervoy and Zelboraf accounted for two-thirds of malignant melanoma drug market in 2011; report

18-09-2012

The launches of Bristol-Myers Squibb's (NYSE: BMY) immunotherapy Yervoy (ipilimumab) and Roche (ROG:…

Bristol-Myers SquibbdabrafenibGlaxoSmithKlineGlobalMarkets & MarketingOncologyPharmaceuticalRochetrametinibYervoyZelboraf

Decline in cardiovascular drugs noted at ESC congress

17-09-2012

This year's European Society of Cardiology (ESC) Congress in Munich, Germany, was a stark example of…

apixabanBristol-Myers SquibbCardio-vascularEliquisMarkets & MarketingPfizerPharmaceuticalResearch

Summit licenses Seglin technology to Bristol-Myers

12-09-2012

UK drug discovery firm Summit Pharmaceuticals (AIM: SUMM) has entered a technology license agreement…

Bristol-Myers SquibbLicensingPharmaceuticalResearchSummit Pharmaceuticals

Teva launches generic Aprovel in UK

30-08-2012

The UK subsidiary of Israel's Teva Pharmaceutical Industries (NYSE: TEVA), the world's largest generic…

AprovelBristol-Myers SquibbCardio-vascularEuropeGenericsMarkets & MarketingSanofiTeva Pharmaceutical Industries

Synergy Pharma gains rights to shingles drug from Bristol-Myers

28-08-2012

US biopharma firm Synergy Pharmaceuticals (Nasdaq: SGYP) has signed an asset purchase agreement with…

Anti-viralsBiotechnologyBristol-Myers SquibbFV-100Mergers & AcquisitionsSynergy Pharmaceuticals

Anti-clotting drugs prasugrel and clopidogrel yield similar results

27-08-2012

The TRILOGY ACS study, the first trial to study patients with acute coronary syndrome who do not undergo…

Bristol-Myers SquibbCardio-vascularDaiichi SankyoEffientEli LillyPharmaceuticalPlavixResearchSanofi

Bristol-Myers drops hep C pill on patient safety issues

24-08-2012

US drug major Bristol-Myers Squibb (NYSE: BMY) has discontinued development of BMS-986094 (formerly known…

Anti-viralsBiotechnologyBMS-986094Bristol-Myers SquibbPharmaceuticalRegulationResearch

Yervoy and Zelboraf rapidly penetrating metastatic patient population in USA and Europe

23-08-2012

In the USA and Europe there is strong physician desire for new therapies for the treatment of early stage…

Bristol-Myers SquibbEuropeMarkets & MarketingNorth AmericaOncologyPharmaceuticalRocheYervoyZelboraf

AstraZeneca and Bristol-Myers complete diabetes alliance expansion; Lilly revises guidance

10-08-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) said yesterday that, following Bristol-Myers Squibb's…

AmylinAstraZenecaBiotechnologyBristol-Myers SquibbDiabetesEli LillyFinancialLicensingPharmaceutical

Pharma partnering dollars continue to decline, Burrill & Co reports

06-08-2012

The recent $3.4 billion partnering agreement announced in July between US pharma company Bristol-Myers…

AmylinAstraZenecaBiotechnologyBristol-Myers SquibbFinancialGlaxoSmithKlineHuman Genome SciencesLicensingMarkets & Marketing

News briefs: setbacks for B-MS hep C drug; Baxter's HyQ

02-08-2012

US drug major Bristol-Myers Squibb (NYSE: BMY) has suspended study drug administration in ongoing Phase…

Anti-viralsBaxter InternationalBMS-986094Bristol-Myers SquibbHyQImmunologicalsNorth AmericaPharmaceuticalRegulationResearch

Patent expiries batter Bristol-Myers 2nd-quarter 2012 results

26-07-2012

Bristol-Myers Squibb (NYSE: BMY) posted second quarter 2012, highlighted by the planned $5.3 billion…

Bristol-Myers SquibbFinancialPharmaceutical

Bristol-Myers brivanib fails in Ph III liver cancer trial

20-07-2012

US drug major Bristol-Myers Squibb (NYSE: BMY) yesterday reported results of the Phase III BRISK-FL clinical…

Bristol-Myers SquibbbrivanibNexavarOncologyPharmaceuticalResearch

120 to 144 of 222 results

Company Spotlight

Fibrotech

Fibrotech

Back to top